Eton Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Eton Pharmaceuticals, Inc. on November 5, 2024, covering events reported as of November 7, 2024. The Company is a Delaware corporation focused on pharmaceutical development, with its principal executive offices in Deer Park, Illinois.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than periodic financial performance.
Material Changes and Events
Under Item 8.01 (Other Events), the Company announced that the United States Patent and Trademark Office (USPTO) granted U.S. Patent No. 12,133,914 for ET-400, a proprietary patented formulation of liquid hydrocortisone. Key details include:
- Patent Scope: Covers a method of using hydrocortisone oral liquid formulations.
- Expiration: The patent expires in 2043.
- Regulatory Status: Expected to be listed in the FDA's Orange Book upon product approval.
- Intellectual Property History: This is the second patent for ET-400, following the first granted in February 2024 (US 11,904,046). An additional U.S. patent application for the product remains under review.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard regulatory context of awaiting FDA approval for Orange Book listing. The primary outlook is the strengthening of the Company's intellectual property portfolio for its lead product candidate.
Investor Verification Checklist
- Verify the status of the FDA approval process for ET-400 to confirm Orange Book listing eligibility.
- Review the full text of the attached press release (Exhibit 99.1) for additional commercialization details.
- Monitor the status of the additional U.S. patent application currently under review.
- Check subsequent filings for any updates on the Company's cash position and funding requirements, as this 8-K does not disclose liquidity metrics.